Abstract

Outcomes with “7 + 3” are often unsatisfactory in acute myeloid leukemia (AML). Trials demonstrating improved outcomes with high-dose cytarabine, addition of cladribine, or escalated anthracycline doses prompted a phase 1/2 study (NCT02044796) of G-CSF, cladribine, high-dose cytarabine, and dose-escalated mitoxantrone (GCLAM) in adults with newly-diagnosed AML or other high-grade myeloid neoplasms. One hundred and twenty-one patients, median age 60 (range 21–81) years, were enrolled. In phase 1, cohorts of 6–12 patients were assigned to 12–18 mg/m2/day of mitoxantrone as part of GCLAM. Because all dose levels were well-tolerated, mitoxantrone at 18 mg/m2 was declared the recommended phase 2 dose (RP2D). 74/94 (79%) patients treated at the RP2D achieved a complete remission (CR; 67/74 without measureable residual disease [MRD]) for an overall MRDneg CR rate of 71% (primary phase 2 endpoint). Seven patients achieved a CR with incomplete blood count recovery (CRi; 7%, 5 MRDneg) for a CR/CRi rate of 81/94 (86%). Four-week mortality was 2%. After adjustment, the MRDneg CR and CR/CRi rates compared favorably to 100 matched controls treated with 7 + 3 at our center and 245 matched patients treated with 7 + 3 on a cooperative group trial. Our data indicate GCLAM with mitoxantrone at 18 mg/m2/day is safe and induces high-quality remissions in adults with newly-diagnosed AML.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Yates JW, Wallace HJ Jr., Ellison RR, Holland JF. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep. 1973;57:485–8.

  2. 2.

    Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults. Lancet. 2013;381:484–95.

  3. 3.

    Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136–52.

  4. 4.

    Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47.

  5. 5.

    Godwin CD, Gale RP, Walter RB. Gemtuzumab ozogamicin in acute myeloid leukemia. Leukemia. 2017;31:1855–68.

  6. 6.

    Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377:454–64.

  7. 7.

    Burnett AK, Russell NH, Hills RK, Hunter AE, Kjeldsen L, Yin J, et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol. 2013;31:3360–8.

  8. 8.

    Holowiecki J, Grosicki S, Robak T, Kyrcz-Krzemien S, Giebel S, Hellmann A, et al. Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study. Leukemia. 2004;18:989–97.

  9. 9.

    Holowiecki J, Grosicki S, Giebel S, Robak T, Kyrcz-Krzemien S, Kuliczkowski K, et al. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. J Clin Oncol. 2012;30:2441–8.

  10. 10.

    Libura M, Giebel S, Piatkowska-Jakubas B, Pawelczyk M, Florek I, Matiakowska K, et al. Cladribine added to daunorubicin-cytarabine induction prolongs survival of FLT3-ITD+normal karyotype AML patients. Blood. 2016;127:360–2.

  11. 11.

    Wierzbowska A, Robak T, Pluta A, Wawrzyniak E, Cebula B, Holowiecki J, et al. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group. Eur J Haematol. 2008;80:115–26.

  12. 12.

    Price SL, Lancet JE, George TJ, Wetzstein GA, List AF, Ho VQ, et al. Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens. Leuk Res. 2011;35:301–4.

  13. 13.

    Jaglal MV, Duong VH, Bello CM, Al Ali NH, Padron E, Fernandez HF, et al. Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure. Leuk Res. 2014;38:443–6.

  14. 14.

    Löwenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361:1235–48.

  15. 15.

    Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361:1249–59.

  16. 16.

    Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.

  17. 17.

    Walter RB, Othus M, Borthakur G, Ravandi F, Cortes JE, Pierce SA, et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol. 2011;29:4417–23.

  18. 18.

    Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116:354–65.

  19. 19.

    Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid Leukemia. J Clin Oncol. 2003;21:4642–9.

  20. 20.

    Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453–74.

  21. 21.

    Walter RB, Gooley TA, Wood BL, Milano F, Fang M, Sorror ML, et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol. 2011;29:1190–7.

  22. 22.

    Araki D, Wood BL, Othus M, Radich JP, Halpern AB, Zhou Y, et al. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission? J Clin Oncol. 2016;34:329–36.

  23. 23.

    Zhou Y, Othus M, Araki D, Wood BL, Radich JP, Halpern AB, et al. Pre- and post-transplant quantification of measurable (‘minimal’) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia. Leukemia. 2016;30:1456–64.

  24. 24.

    Petersdorf SH, Kopecky KJ, Slovak M, Willman C, Nevill T, Brandwein J, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121:4854–60.

  25. 25.

    Othus M, Wood BL, Stirewalt DL, Estey EH, Petersdorf SH, Appelbaum FR, et al. Effect of measurable (‘minimal’) residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia. Leukemia. 2016;30:2080–3.

  26. 26.

    Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1–10.

  27. 27.

    Bello C, Yu D, Komrokji RS, Zhu W, Wetzstein GA, List AF, et al. Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome. Cancer. 2011;117:1463–9.

  28. 28.

    Jabbour E, Ghanem H, Huang X, Ravandi F, Garcia-Manero G, O’Brien S, et al. Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis. Clin Lymphoma Myeloma Leuk. 2014;14:93–97.

  29. 29.

    Othus M, Kantarjian H, Petersdorf S, Ravandi F, Godwin J, Cortes J, et al. Declining rates of treatment-related mortality in patients with newly diagnosed AML given ‘intense’ induction regimens: a report from SWOG and MD Anderson. Leukemia. 2014;28:289–92.

  30. 30.

    Percival ME, Tao L, Medeiros BC, Clarke CA. Improvements in the early death rate among 9380 patients with acute myeloid leukemia after initial therapy: a SEER database analysis. Cancer. 2015;121:2004–12.

  31. 31.

    Halpern AB, Culakova E, Walter RB, Lyman GH. Association of risk factors, mortality, and care costs of adults with acute myeloid leukemia with admission to the intensive care unit. JAMA Oncol. 2017;3:374–81.

  32. 32.

    Atallah E, Cortes J, O’Brien S, Pierce S, Rios MB, Estey E, et al. Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. Blood. 2007;110:3547–51.

  33. 33.

    Lee JH, Kim H, Joo YD, Lee WS, Bae SH, Zang DY, et al. Prospective randomized comparison of idarubicin and high-dose daunorubicin in induction chemotherapy for newly diagnosed acute myeloid leukemia. J Clin Oncol. 2017;35:2754–63.

  34. 34.

    Löwenberg B, Pabst T, Maertens J, van Norden Y, Biemond BJ, Schouten HC, et al. Therapeutic value of clofarabine in younger and middle-aged (18–65 years) adults with newly diagnosed AML. Blood. 2017;129:1636–45.

  35. 35.

    Hourigan CS, Gale RP, Gormley NJ, Ossenkoppele GJ, Walter RB. Measurable residual disease testing in acute myeloid leukaemia. Leukemia. 2017;31:1482–90.

Download references

Acknowledgements

The authors wish to gratefully acknowledge the important contributions of the late Dr. Stephen H. Petersdorf to SWOG and to study S0106. Research reported in this publication was supported by the National Institutes of Health under Award Numbers U10-CA180888, U10-CA180819, and U10-CA180828. A.B.H., S.A.B., and A.A. were supported by a fellowship training grant from the National Heart, Lung, and Blood Institute/National Institutes of Health (T32-HL007093). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. A.B.H. is the recipient of a Conquer Cancer Foundation/American Society of Clinical Oncology (ASCO) Young Investigator Award. R.B.W. is a Leukemia & Lymphoma Society Scholar in Clinical Research.

Author information

Affiliations

  1. Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA

    • Anna B. Halpern
    • , Emily M. Huebner
    • , Bart L. Scott
    • , Pamela S. Becker
    • , Mary-Elizabeth M. Percival
    • , Kaysey F. Orlowski
    • , Frederick R. Appelbaum
    • , Elihu H. Estey
    •  & Roland B. Walter
  2. Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA

    • Anna B. Halpern
    • , Pamela S. Becker
    • , Mary-Elizabeth M. Percival
    • , Paul C. Hendrie
    • , Kelda M. Gardner
    • , Elihu H. Estey
    •  & Roland B. Walter
  3. Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

    • Megan Othus
  4. SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

    • Megan Othus
  5. Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA

    • Bart L. Scott
    •  & Frederick R. Appelbaum
  6. Deparment of Pharmacy Services, University of Washington, Seattle, WA, USA

    • Tara L. Chen
  7. Hematology/Oncology Fellowship Program, University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA, USA

    • Sarah A. Buckley
    •  & Asma Anwar
  8. Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL, USA

    • Harry P. Erba
  9. Department of Epidemiology, University of Washington, Seattle, WA, USA

    • Roland B. Walter

Authors

  1. Search for Anna B. Halpern in:

  2. Search for Megan Othus in:

  3. Search for Emily M. Huebner in:

  4. Search for Bart L. Scott in:

  5. Search for Pamela S. Becker in:

  6. Search for Mary-Elizabeth M. Percival in:

  7. Search for Paul C. Hendrie in:

  8. Search for Kelda M. Gardner in:

  9. Search for Tara L. Chen in:

  10. Search for Sarah A. Buckley in:

  11. Search for Kaysey F. Orlowski in:

  12. Search for Asma Anwar in:

  13. Search for Frederick R. Appelbaum in:

  14. Search for Harry P. Erba in:

  15. Search for Elihu H. Estey in:

  16. Search for Roland B. Walter in:

Conflict of interest

The authors declare that they have no conflict of interest.

Corresponding author

Correspondence to Roland B. Walter.

Electronic supplementary material

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/s41375-018-0135-8

Further reading